Pfizer Inc. said Thursday it agreed to a $5.29 billion deal with the U.S. to provide enough supplies of its promising Covid-19 pill to treat 10 million people, should health regulators give it the green light.
The company’s antiviral drug, Paxlovid, is under review by the U.S. Food and Drug Administration, and a decision could come before the end of the year.
